Immune Pharmaceuticals Inc (fka IMNPQ)

[Timing101]

Facts are Facts folks. Just wait , more to come, they have until the end of the Month.
--
Remember if the post has no LINKS (or just part posting quote) then it STINKS.
--
1. SEC . Why listen to folks posting here . Just look it up. There is a reason it is "temporary": They will file a SEC FORM 211 and all will move forward to get approved by FINRA.
https://www.otcmarkets.com/stock/IMNPQ/news/SEC-Suspension-of-Trading?id=298908
--
2. Read the 8-k and pay attention to Item 8.01 , Other Events. : There is an OLD IMNPQ (the apple) and there is going to be a New and Improved IMNP with out the "Q" (the orange). They are in process of doing that now, so do not listen to folks talking about the 'apple" (OLD) , now it is all about the NEW ORANGE (NEW IMNP) .
https://www.otcmarkets.com/filing/html?id=14865049&guid=atepUqpWCxxu93h
--
3. Pay close attention to the statement in the 8-K .
Quote" Mr Daudpota has secured the full support of United General LTD a UK investment firm and liquidity provider, Where he also he holds a board position."
Item 8.01
https://www.otcmarkets.com/filing/html?id=14865049&guid=atepUqpWCxxu93h
--
4. United General . Both Mr. Daudpota and Mr. Shaw are officers there, Private Company going Public in some format now. https://opencorporates.com/companies/gb/11574155
--
5. NOTE these very IMPORTANT STATEMENTS in the 8-k , confirmed in EDGAR and SEC as factual . They are in process of filing form SEC 211.
https://www.otcmarkets.com/filing/html?id=14865049&guid=atepUqpWCxxu93h
*
*The proposed merger plan will separate the Immune Pharmaceuticals LLC (In chapter 7) into the surviving entity that will not be subject to chapter 7 bankruptcy.



*Holders of common stock under this structure will retain a shareholding in the surviving public company and will be afforded as such shareholder rights in the new operating pharmaceutical company post-merger.


* Upon completion of the merger, we will appoint a new board and apply to have the bankruptcy status lifted from Finra.